Large gap with delayed quotes
|
Last quote
01/06/2025 -
17:31:17
|
Bid
01/06/2025 -
17:19:56
|
Bid Volume |
Ask
01/06/2025 -
17:19:52
|
Ask Volume |
|---|---|---|---|---|
|
64.60
+0.40
(
+0.62% )
|
64.70
|
105 |
64.80
|
1 |
Analysis date: 03.01.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 31.12.2024.
Interest
Very weak
Very weak
Very weak interest since 31.12.2024.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 20.12.2024 at a price of 59.70.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, at its current price the stock is strongly overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 01.10.2024), the stock traded below its moving average. The confirmed Technical Reverse (Tech Reverse + 1.75%) point is
4wk Rel Perf
4.64%
4.64%
The four week relative overperformance versus STOXX600 is 4.64%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 05.11.2024.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 1.95%.
Mkt Cap in $bn
1.19
1.19
With a market capitalization <$2bn, COSMO PHARMACEUTICALS is considered a small-cap stock.
G/PE Ratio
-0.09
-0.09
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
36.51
36.51
The estimated PE is for the year 2026.
LT Growth
-3.39%
-3.39%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
3
3
Over the last seven weeks, an average of 3 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
77
77
For 1% of index variation, the stock varies on average by 0.77%.
Correlation
0.33
0.33
Stock movements are strongly independent of index variations.
Value at Risk
12.68
12.68
The value at risk is estimated at CHF 12.68. The risk is therefore 19.75%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
10.11.2017
10.11.2017